Amphetamine Salts vs Dextroamphetamine for ADHD and Narcolepsy
Core Pharmacological Differences
Both amphetamine salts (mixed amphetamine salts/MAS, such as Adderall) and dextroamphetamine are highly effective first-line treatments for ADHD with comparable efficacy, but they differ in composition and pharmacokinetic profiles. 1
Composition and Mechanism
Mixed amphetamine salts contain a 3:1 ratio of d-amphetamine to l-amphetamine isomers (specifically: dextroamphetamine sulfate, dextro- and levoamphetamine sulfate, dextroamphetamine aspartate, levoamphetamine aspartate, and dextroamphetamine saccharate), while dextroamphetamine contains only the d-isomer. 2, 3
Both medications work as CNS stimulants by inhibiting dopamine and norepinephrine transporters, VMAT-2, and monoamine oxidase activity, but the inclusion of l-amphetamine in MAS may provide slightly different peripheral and central effects. 4, 2
The different delivery profiles result in pharmacological and pharmacokinetic differences that contribute to varying effects in clinical treatment, though both achieve similar therapeutic outcomes. 2
Efficacy Comparison
ADHD Treatment
For ADHD, both medications demonstrate 70-80% response rates with large effect sizes (approximately 1.0), significantly superior to non-stimulant alternatives (effect size ~0.7). 5, 4, 6
Mixed amphetamine salts at an average dose of 54 mg/day (administered in 2 daily doses) produced a 42% decrease in ADHD Rating Scale scores with 70% of subjects achieving clinically significant improvement (>30% reduction) versus 7% with placebo. 3
Dextroamphetamine at doses of 5 mg three times daily to 20 mg twice daily is equally effective for reducing ADHD symptom severity as rated by both clinicians and patients. 7
The American Academy of Child and Adolescent Psychiatry recommends that an individual's response to one amphetamine formulation versus another is idiosyncratic—approximately 40% respond to both formulations equally, while 40% respond preferentially to only one. 5
Narcolepsy Treatment
For narcolepsy with cataplexy, dextroamphetamine is the preferred choice as it demonstrates clinically significant improvements in BOTH excessive daytime sleepiness AND cataplexy, receiving a CONDITIONAL recommendation from guidelines. 4
Total daily doses of 60 mg for dextroamphetamine have been shown to significantly reduce daytime sleepiness in narcolepsy patients. 1
Dosing Considerations
Mixed Amphetamine Salts (Adderall)
Start at 10 mg once daily in the morning for adults, titrating by 5 mg weekly up to a maximum of 40-50 mg daily. 5, 7
For children and adolescents, doses can be titrated up to 40 mg daily with 70-80% response rates when properly titrated. 5
Low-dose therapy (mean 10.77 mg/day or 0.14 mg/kg/day) produced positive responses in 54% of adults with ADHD, though higher doses are typically needed for optimal control. 8
Dextroamphetamine
Recommended dosing for adults is 5 mg three times daily to 20 mg twice daily, with a maximum of 60 mg daily. 1, 7
Immediate-release preparations provide clinical benefits for 3-5 hours after oral dosing, requiring multiple daily doses to maintain improvement. 1
Safety Profile and Adverse Effects
Common Adverse Effects
Mixed amphetamine salts commonly cause appetite suppression, sleep disturbances, cardiovascular effects (increased blood pressure and heart rate), and in vulnerable individuals, acute anxiety symptoms. 5, 8
Dextroamphetamine adverse effects include sweatiness, edginess, weight gain, loss of appetite, and irritability. 4
Amphetamines typically cause greater effects on appetite and sleep compared to methylphenidate due to longer excretion half-lives. 5
Critical Safety Warnings
BLACK BOX WARNING: Both medications carry HIGH potential for abuse and prolonged administration may lead to dependence. 4
Both are DEA Schedule II controlled substances with significant abuse potential, though long-acting formulations (like lisdexamfetamine) have demonstrated reduced abuse liability compared to immediate-release amphetamines. 2, 9
Contraindications include active stimulant abuse, symptomatic cardiovascular disease, uncontrolled hypertension, and concurrent use with MAO inhibitors (risk of severe hypertension and cerebrovascular accidents). 5, 7
Cardiovascular Monitoring
Monitor blood pressure and pulse at baseline and regularly during treatment, as 5-15% of patients may experience clinically significant cardiovascular changes. 5, 4
If tachycardia or elevated blood pressure develops, discontinue or decrease dose, or consider switching to non-stimulant alternatives (atomoxetine, guanfacine, clonidine). 4
Special Populations
Pregnancy and Breastfeeding
Both medications may cause fetal harm based on animal data, though human data is insufficient. 4
Therapeutic use of mixed amphetamine salts during pregnancy does not appear associated with major congenital malformations or significant adverse developmental outcomes, though possible small increased risks for cardiac malformations and preeclampsia have been reported. 5, 4
Comorbid Conditions
The presence of anxiety does not contraindicate stimulant use but requires careful monitoring—stimulants can improve executive function deficits which may indirectly reduce anxiety related to functional impairment. 5
However, mixed amphetamine salts may precipitate acute anxiety in vulnerable individuals, particularly those with comorbid anxiety disorders. 8
Stimulants continue to ameliorate ADHD symptoms in the presence of other comorbid Axis I disorders (conduct disorder, anxiety disorder) and may show positive benefit on the comorbid condition. 1
Substance Use History
Exercise particular caution when prescribing stimulants to adults with comorbid substance abuse disorder—consider long-acting formulations with lower abuse potential or non-stimulant alternatives as first-line. 1, 7
Daily stimulant treatment can reduce ADHD symptoms and risk for relapse to substance use in patients with comorbid substance dependence, with methylphenidate-treated groups showing significantly higher proportions of drug-negative urines. 5
Clinical Decision Algorithm
When to Choose Mixed Amphetamine Salts
Choose MAS when the patient has ADHD as the primary indication and no history of preferential response to dextroamphetamine alone. 5, 2
MAS offers the advantage of a balanced isomer ratio that may provide more consistent symptom control throughout the day for some patients. 2
Long-acting MAS formulations provide enhanced duration of action (8-12 hours) with once-daily dosing, improving medication adherence. 5, 2
When to Choose Dextroamphetamine
Choose dextroamphetamine when the patient has narcolepsy with cataplexy, as it demonstrates superior efficacy for both excessive daytime sleepiness AND cataplexy control. 4
Consider dextroamphetamine if the patient has previously responded preferentially to this specific isomer or experienced intolerable side effects with MAS. 5
When to Switch Between Formulations
If response to one amphetamine formulation is inadequate after proper titration, trial the other formulation before considering non-stimulants, as approximately 40% of patients respond preferentially to only one. 5
If both amphetamine formulations fail or cause intolerable side effects, switch to methylphenidate class before considering non-stimulants. 5
Common Pitfalls to Avoid
Do NOT assume both formulations will produce identical responses in all patients—individual pharmacogenetic differences mean some patients respond preferentially to one formulation. 5
Do NOT underdose—many treatment failures result from inadequate titration rather than true medication resistance. Adults often require 20-40 mg daily of MAS or equivalent dextroamphetamine doses for optimal control. 5, 3
Do NOT prescribe immediate-release formulations for once-daily use—they provide only 3-5 hours of coverage and require multiple daily doses to maintain therapeutic effect. 1
Do NOT discontinue effective treatment solely due to concerns about "taking stimulants long-term"—untreated ADHD is associated with increased risk of accidents, substance abuse, criminality, and functional impairment. 5
Do NOT combine with MAO inhibitors—wait at least 14 days after MAOI discontinuation before initiating amphetamines. 7